PTC Therapeutics (PTCT) announced that the U.S. Food and Drug Administration, FDA, has accepted for filing the New Drug Application, NDA, for ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

Novo Nordisk (NYSE:NVO) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies ...

Dr. Bruce Lahn, Chief Scientist at VectorBuilder, commented, "Congratulations to Chengdu Ucello on the FDA IND approval of UC101 ... cell line for lentiviral vector manufacturing.

approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline.

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.

That’s because there is an inverse relationship between presidential approval ratings and the stock market, according to an analysis conducted by Ned Davis Research. Donald Trump’s approval ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy. The Food and Drug ...

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...